TriSalus Life Sciences, Inc.
TriSalus Life Sciences, Inc.
Your view on TLSI
Overview
What the company does, where it operates, and who runs it.
About TriSalus Life Sciences, Inc.
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Mary T. Szela B.S.N.,
- Headquarters
- 6272 West 91st Avenue, Westminster, CO, US
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Mary T. Szela B.S.N.,
- Headquarters
- 6272 West 91st Avenue, Westminster, CO, US
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors.
It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers.
The company is based in Westminster, Colorado.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for TriSalus Life Sciences, Inc., and the rating behind it. TLSI last traded at $4.67; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for TriSalus Life Sciences, Inc.. Starting points for TriSalus Life Sciences, Inc.: EPS -$0.48, beta 0.44 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for TriSalus Life Sciences, Inc.. TriSalus Life Sciences, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for TriSalus Life Sciences, Inc.. Trailing twelve-month EPS for TriSalus Life Sciences, Inc. stands at -$0.48. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for TriSalus Life Sciences, Inc.. TriSalus Life Sciences, Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
TriSalus Life Sciences, Inc. valued side by side against its closest peers. TriSalus Life Sciences, Inc. is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold TriSalus Life Sciences, Inc., and how their positions are changing. At a $287.2M market value, institutional positions materially move TriSalus Life Sciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by TriSalus Life Sciences, Inc. executives and directors. Shares of TriSalus Life Sciences, Inc. have traded between $3.42 and $5.88 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming TriSalus Life Sciences, Inc.. TriSalus Life Sciences, Inc. is a $287.2M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming TriSalus Life Sciences, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for TriSalus Life Sciences, Inc.. Coverage tracks TriSalus Life Sciences, Inc. within Medical - Devices (Healthcare). Press releases and market coverage, newest first.